Challenges in anticancer drug R&D in China - 04/02/19
Doi : 10.1016/S1470-2045(18)30865-9
Shen Zhao a, Cheng Lv b, Jifang Gong c, Fang Wenfeng a, Xichun Hu d, Yi Ba e, Chen Xiaoyuan f, Yang Zhimin f, Lin Shen c, Li Zhang a 
on behalf of the
on behalf of the
Chinese Phase 1 Oncology trial Consortium
a Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China
b Covance, Shanghai, China
c Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Haidian, Beijing, 100142, China
d Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
e Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
f National Center for Drug Evaluation, China Food and Drug Administration, Beijing, China
Le texte complet de cet article est disponible en PDF.
© 2019
Elsevier Ltd. Tous droits réservés.© 2019
Thierry Berrod, Mona Lisa Production/SPL. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 20 - N° 2
P. 183-186 - février 2019 Retour au numéro
Article précédent
- Betel nut chewing in high-income countries—lack of awareness and regulation
- Matt Lechner, Charles E Breeze, Francis Vaz, Valerie J Lund, Bhik Kotecha
- DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how?
- Ka On Lam, Chi Chung Tong, Victor Ho Fun Lee, Mai Yee Luk, Ching Wan Lam
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?